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SRI and TDI at mid-ventricle in systole 
peak systolic value Control (n=34) No-CHF (n=28) CHF (n=26) 
IVS SRI -1.8±0.5 -1.2±0.7 1" -0.7±0.5"i" ** 
LAT SRI -t .7±0.6 -1.4±0.5 * -0,8±0.51. ** 
INF SRI -1.6±0.7 -1.2±0.6 * -0.8±0.6 1. ** 
IVS TDI 3.7¢1.1 3.9±1.4 2.5±1.2 1" 1.1. 
LAT TDI 3.4±1.8 2.5±1.2 * 2.4±1.3 * 
INF TDI 4.0±1.2 3.7±1.3 2.4±1.3 1. 1.1. 
*:P<0.05 vs.Control 1": P<0.001 vs. Control **:P<0.05 vs. No-CHF 1"'i-:P<0.001 vs.No- 
CHF 
POSTER SESSION 
1135 Experimental and Clinical Heart 
Transplantation 
Monday, March 18, 2002, 3:00 p.m.-5:00 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: 3:00 p.m.-4:00 p.m. 
1135-141 Long-Term Beneficial Effects of Neonatal 
Cardiomyocytes on Left Ventricular Ejection Fraction, 
Regional Wall Motion, and Scar Thickness After 
Transplantation Into Infarcted Rat Hearts 
Jochen Muller-Ehmsen. Kirk L. Peterson, Larry Kedes, Peter Whittaker, Joan S. Dow, 
Robert A. Kloner, Heart Institute Good Samaritan Hospital, Los Angeles, Cafifornia. 
The long-term effects of cardiac cell transplantation on myocardial dysfunction are 
unknown. We tested, therefore, the impact of neonatal cardiomyocytes on cardiac con- 
tractility, left ventricular (LV) volumes and LV geometry 6 months after transplantation into 
infarcted hearts. Cardiomyocytes from male neonatal Fischer 344 rats (1-2 d, 3-5 x 106/ 
50 IJI) or medium were injected into the infarcts of adult syngeneic female animals 1 week 
after left coronary artery ligation. LV angiography 6 months after cell transplantation 
revealed a greater ejection fraction in treated animals than in control (0.36±0.03 vs. 
0.25±0.02, both n=9, P<0.01). 55.1±7.3% of the myocardial infarct zone was dyskinetic 
in control rats vs. 29.5:~8.3% in cell treated rats (P=0.035). Average chordat shortening 
within the myocardial infarct zone was negative in controls but positive in treated rats 
(P=0.02). LV hemodynamics (n=9 each) showed similar enddiastolic pressures, maximal 
systolic pressures and maximal rates of rise and fall of ventricular pressure (+dP/dt, -dP/ 
dt). Post mortem, hearts were fixed in distension (10 mmHg intracavity pressure), and LV 
geometry data were obtained. LV volumes and infarct sizes were similar in the treated 
group as in control (0.42±0.02 vs. 0.45±0.03 ml and 31.5¢1.7 vs. 34.2+2.8%), but scar 
thickness was greater in treated animals (909±97 1~m vs. 619±41 I~m, P<0.02). 
Previously, we have shown that more than half of neonatal cardiomyocytes urvive for at 
least 6 months after transplantation into infarcted hearts. Transplanted neonatal cells 
reduced regional dyskinesis and had a small beneficial effect on systolic contraction. For 
the first time, it has been shown that cell transplantation therapy improves long-term in 
vivo global and regional left ventricular function after myocardial infarction. 
1135-142 Ident i f i cat ion  o f  Genes Involved in Acute Rejection 
Following Heart Transplantation in a Murine Model: Use 
of cDNA Arrays 
Ana L. S. Roussoulieres, Olivier Raisky, Lara Chalabreysse, George Dureau, Pascale 
Boissonnat, Jean-Francois Obedia, Francoise Thivolet-Bejui, John L. McGregor. Hopital 
Cardiologique Louis Pradel, Lyon, France, INSERM U331, Lyon, France. 
Objectives: To identify gene clusters that are over- or under-expressed, in acute rejection 
in a murine model of heterotopic heart transplantation. 
Methods: Hearts from Balb/c mice were transplanted heterotopically in the abdomen of 
Balb/c (isografts) and C57BIJ6 mice (ailografts). The mice did not receive immunosup- 
pressive treatment. The rejection in the allograft group, was confirmed by the presence of 
lynphocytic infiltrate and myocyte damage using light microscopy. Total RNA was 
extracted from mice hearts that were not transplanted (group NT), from isografts (group I) 
and from allografts (group A). The isolated RNA, DNase treated, was amplified and 
labelled with P32 in a reverse transcriptase reaction. Each probe was hybridised to cDNA 
arrays containing 1176 genes (Atlas Mouse 1.2 Array-Clontech, CA). The relative 
expression levels of a given cDNA from two different RNA sources could be compared 
using the software Atlas 1.01-Clontach. 
Results: Transcription profile was obtained for the three subgroups (NT, I, A). In analys- 
ing these experiments we find that 11 genes were found upregulated in the acute rejec- 
tion group (A) when compared to the control group (NT). Upregulatad genes, include 
Macrophage Inflammatory Protein 1 beta (MIP-1 beta: 272'fold), Interferon Inducible Pro- 
tein 1 (46 fold), Interferon Regulatory Factor 1 (21 fold), Signal Transducer and Activator 
of Transcription 1 (14 fold). Twelve genes were found downregulated in the acute rejec- 
tion group as the VE-Cadherin (17 fold). Validation by immunohistochemistry confirms 
the overexpression of MIP-1 beta and underexpression of VE-Cadherin in the acute 
rejection group (group A). 
Conclusion: Our results suggest that the production of MIP-1 beta and the suppression of 
the VE-Cadherin production by the endothelial cells may participate in the early phase of 
an acute rejection, indeed, these proteins may be implicated in the regulation of leuko- 
cyte recruitment and migration into the myocardial tissue, cDNA arrays offers a powerful 
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tool to study transcription profile patterns in acute allograff rejection. Such transcription 
profiles may be of great help in identifiJing new diagnostic and/or therapeutic tools in 
acute rejection. 
1135-143 Mesenchymal Stem Cell Therapy Prevents Deterioration 
of  Left  Ventricular Function in a Porcine Myocardial 
Infarction Model 
Mohammed S. Qaw~lm, Kaname Takizawa, Malka Frantzen, Robb MecLellan, Michael 
Lill, Michael C. Fishbein, Takashi Miyamoto, Raj Makkar, Cedars-Sinai Medical Center, 
Los Angeles, California. 
Background: Bone marrow derived mesenchymal stem cells (MSC) are capable of dif- 
ferentiating into cardiomyocytes in-vitro. In rodent models of myocardial infarction 
implantation of MSC improves ventricular function. We aimed to test the hypothesis that 
a similar beneficial affect of MSC therapy may be observed in a large animal model of 
myocardial infarction. 
Methods: To test this hypothesis, we developed a porcine model of LV dysfunction. An 
apical myocardial infarction was induced by coil embolization of the distal LAD. Biplane 
ventriculography was used to measure ejection fraction (EF) pre and post-ML At one 
month post-MI, animals underwent thoracotomy and epicardial injection into the apical 
scar (27 g needle, 3 ml final volume) of either 150 million MSC (cell group) or growth 
media alone (placebo group). Prior to injection, MSC were labeled in-vitro with BrdU. At 3 
months post-MI (2 months post.injection), animals were sacrificed and the heart removed 
for histology. 
Results: Ejection fraction decreased in both groups 1 month after MI (before cell trans- 
plantation), by 8% (placebo group, n=8) and 5% (cell group, not significantly different, 
n=10). At 3 months post-M1 (2 months after cell transplantation) ejection fraction had 
decreased from the pre-MI baseline by 17% (n=8) in the placebo group versus 5% (n=5) 
in the cell therapy group (p<O.05). Histology revealed BrdU labeled MSC in infarct tissue 
2 months post-cell transplantation. 
Conclusions: Epicardial injection of mesenchymal ste~ cells into scar tissue prevents 
further adverse deterioration in LV function in a chronic MI animal model. Mesechymal 
stem cells are capable of surviving in infarct tissue up to 2 months following transplanta- 
tion, 
1135-144 The Growing Threat of Malignancies Under Various 
Heart Transplant Immunosuppreasive Regimens From s 
Single Institution 
Bijal Patel, Maria L, Espejo, Eric Sue, Sheryllene Go, Jon A. Kobashigawa. University of 
California, Los Angeles, Los Angeles, California. 
Background: MaLignancy in heart transplant recipients has been reported to occur in 
approximately 5% of patients. This incidence may be an underestimation as average 
time on immunosuppressive medication and average age of the heart transplant recipient 
increases. It is also not clear whether different immunosuppressive regimens lead to 
more or less development of malignancies. Method: We reviewed 705 adult heart trans- 
plant patients with five-year followup from our institution (standardized followup proto- 
cols) to assess the incidence of malignancies and the impact of various 
immunosuppressive regimens. Average recipient age was 53.6 years and average fol- 
Iowup tome was 5.1 years. Patients were grouped into the following immunosupprassive 
regimens (at the time of initial hospital discharge): Group 1 (n=458), cyclosporine (CSA)/ 
azathioprine (AZA); Group 2 (n=33), tacrolimus (TAC)/AZA; Group 3 (n=137), CSN 
myphenolate mofetil (MMF); Group 4 (n=30), TAC/MMF. Results: For five-year follow-up, 
malignancies were observed in 141 of 705 (20.0%) heart transplant recipients. This 
included; 23.1% Group 1, 18.1% Group 2, 19.0% Group 3, and 6.7% Group 4 patients. 
The more common malignancies were similar in incidence in all groups and are seen in 
the table. Conclusion: The incidence of malignancies following head transplantation is 
higher than reported despite immunosuppressive regimens. Further study and preventive 
measures are needed to reduce the incidence of this significant and growing} problem. 
Group N % Skin % Lymphoma % Lung % Colon % Prostate % Breast 
CSA/AZA 458 10.5 2.6 2.0 0.9 1.7 1.3 
TAC/AZA 33 15.1 0 3.0 0 0 0 
CSNMMF 137 8.8 1.5 1.5 0.2 2.2 1.5 
TAC/MMF 30 3.3 3.3 0 0 0 0 
